Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Cardiol Therapeutics Inc Class A
CRDLCardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. Address: 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5
Analytics
Objectif de Cours de WallStreet
13.71 CADRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés CRDL
Analyse des dividendes CRDL
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes CRDL
Valorisation des titres CRDL
financières CRDL
Résultats | 2019 | Dynamique |